S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Syneos Health Stock Forecast, Price & News

-1.42 (-1.44%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
385,100 shs
Average Volume
849,470 shs
Market Capitalization
$10.08 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SYNH News and Ratings via Email

Sign-up to receive the latest news and ratings for Syneos Health and its competitors with MarketBeat's FREE daily newsletter.

Syneos Health logo

About Syneos Health

Syneos Health, Inc. provides outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded in 1998 and is headquartered in Morrisville, NC.


Syneos Health (NASDAQ:SYNH) Shares Gap Up to $95.72
November 15, 2021 |  americanbankingnews.com
Syneos Health (NASDAQ:SYNH) Trading Down 6.3%
November 12, 2021 |  americanbankingnews.com
Labcorp Is in Talks to Merge Part of Covance With Syneos
November 11, 2021 |  finance.yahoo.com
NOVN: KINSOLUS: A Solution for Molluscum
November 11, 2021 |  finance.yahoo.com
Syneos Health to Present at Upcoming Investor Conferences
November 11, 2021 |  finance.yahoo.com
Syneos Health, Inc.(SYNH)
November 6, 2021 |  fool.com
Syneos Health's Return On Capital Employed Overview
November 3, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Commercial physical research
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$4.42 billion
Cash Flow
$4.77 per share
Book Value
$32.02 per share


Net Income
$192.79 million
Pretax Margin




Free Float
Market Cap
$10.08 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.97 out of 5 stars

Medical Sector

673rd out of 1,388 stocks

Commercial Physical Research Industry

9th out of 27 stocks

Analyst Opinion: 1.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Syneos Health (NASDAQ:SYNH) Frequently Asked Questions

Is Syneos Health a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Syneos Health stock.
View analyst ratings for Syneos Health
or view top-rated stocks.

How has Syneos Health's stock price been impacted by Coronavirus?

Syneos Health's stock was trading at $57.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SYNH stock has increased by 69.7% and is now trading at $97.23.
View which stocks have been most impacted by COVID-19

Are investors shorting Syneos Health?

Syneos Health saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,510,000 shares, a drop of 27.8% from the October 31st total of 2,090,000 shares. Based on an average trading volume of 585,000 shares, the days-to-cover ratio is currently 2.6 days.
View Syneos Health's Short Interest

When is Syneos Health's next earnings date?

Syneos Health is scheduled to release its next quarterly earnings announcement on Thursday, February 17th 2022.
View our earnings forecast for Syneos Health

How were Syneos Health's earnings last quarter?

Syneos Health, Inc. (NASDAQ:SYNH) posted its quarterly earnings results on Wednesday, November, 3rd. The company reported $1.22 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.17 by $0.05. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.34 billion. Syneos Health had a trailing twelve-month return on equity of 11.71% and a net margin of 5.04%. The business's revenue for the quarter was up 22.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.93 earnings per share.
View Syneos Health's earnings history

What guidance has Syneos Health issued on next quarter's earnings?

Syneos Health updated its FY 2021 earnings guidance on Wednesday, November, 10th. The company provided EPS guidance of $4.350-$4.490 for the period, compared to the Thomson Reuters consensus estimate of $4.350. The company issued revenue guidance of $5.20 billion-$5.28 billion, compared to the consensus revenue estimate of $5.25 billion.

What price target have analysts set for SYNH?

7 equities research analysts have issued twelve-month price targets for Syneos Health's shares. Their forecasts range from $80.00 to $122.00. On average, they expect Syneos Health's stock price to reach $98.44 in the next year. This suggests a possible upside of 1.2% from the stock's current price.
View analysts' price targets for Syneos Health
or view top-rated stocks among Wall Street analysts.

Who are Syneos Health's key executives?

Syneos Health's management team includes the following people:
  • Alistair John Macdonald, Chief Executive Officer & Director (LinkedIn Profile)
  • Jason Michael Meggs, Chief Financial Officer & Executive Vice President
  • Larry A Pickett, Chief Information & Digital Officer
  • Michelle Keefe, President-Commercial Solutions
  • Paul D. Colvin, Chief Business Officer

What is Alistair Macdonald's approval rating as Syneos Health's CEO?

322 employees have rated Syneos Health CEO Alistair Macdonald on Glassdoor.com. Alistair Macdonald has an approval rating of 82% among Syneos Health's employees.

What other stocks do shareholders of Syneos Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Pfizer (PFE), Square (SQ), Advanced Micro Devices (AMD), Boeing (BA), Alibaba Group (BABA), ICON Public (ICLR), Netflix (NFLX), AbbVie (ABBV) and Intel (INTC).

What is Syneos Health's stock symbol?

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Who are Syneos Health's major shareholders?

Syneos Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (9.57%), BlackRock Inc. (8.88%), Capital World Investors (2.48%), Mackenzie Financial Corp (2.25%), Massachusetts Financial Services Co. MA (2.12%) and Cooke & Bieler LP (2.08%). Company insiders that own Syneos Health stock include Alistair Macdonald, Donna Hildebrand Kralowetz, International Corp/Ma Advent, Jason M Meggs, John L Maldonado, John M Dineen, Jonathan Olefson, Linda S Harty, Mark E Jagiela, Matthew E Monaghan, Michelle Keefe, Paul Colvin, Robert Parks, Thomas H Lee Advisors, Llc and Tom Allen.
View institutional ownership trends for Syneos Health

Which major investors are selling Syneos Health stock?

SYNH stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Mackenzie Financial Corp, Polar Capital Holdings Plc, Bank of New York Mellon Corp, Jennison Associates LLC, Balyasny Asset Management LLC, Balyasny Asset Management LLC, and Reinhart Partners Inc.. Company insiders that have sold Syneos Health company stock in the last year include Alistair Macdonald, Donna Hildebrand Kralowetz, International Corp/Ma Advent, Jason M Meggs, John L Maldonado, Jonathan Olefson, Linda S Harty, Mark E Jagiela, Matthew E Monaghan, Michelle Keefe, Thomas H Lee Advisors, Llc, and Tom Allen.
View insider buying and selling activity for Syneos Health
or view top insider-selling stocks.

Which major investors are buying Syneos Health stock?

SYNH stock was bought by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Assenagon Asset Management S.A., Fuller & Thaler Asset Management Inc., Dana Investment Advisors Inc., Strs Ohio, Stephens Investment Management Group LLC, BlackRock Inc., and Point72 Asset Management L.P.. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs, John M Dineen, and Paul Colvin.
View insider buying and selling activity for Syneos Health
or or view top insider-buying stocks.

How do I buy shares of Syneos Health?

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syneos Health's stock price today?

One share of SYNH stock can currently be purchased for approximately $97.23.

How much money does Syneos Health make?

Syneos Health has a market capitalization of $10.08 billion and generates $4.42 billion in revenue each year. The company earns $192.79 million in net income (profit) each year or $2.39 on an earnings per share basis.

How many employees does Syneos Health have?

Syneos Health employs 25,000 workers across the globe.

What is Syneos Health's official website?

The official website for Syneos Health is www.syneoshealth.com.

Where are Syneos Health's headquarters?

Syneos Health is headquartered at 1030 Sync Street, Morrisville NC, 27560.

How can I contact Syneos Health?

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at (919) 876-9300, via email at [email protected], or via fax at 919-876-9360.

This page was last updated on 12/6/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.